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The neurogenetic prototypic disease on which we chose to test our
gene therapy strategy is Canavan disease (CD). CD is an
autosomal recessive leukodystrophy associated with spongiform
degeneration of the brain. At present the disease is uniformly fatal
in affected probands. CD is characterized by mutations in the
aspartoacylase (ASPA) gene, resulting in loss of enzyme activity.
In this review, recent evidence is summarized on the etiology and
possible treatments for CD. In particular, we discuss two gene
delivery systems representing recent advances in both viral and
liposome technology: a novel cationic liposome-polymer-DNA
(LPD) complex, DCChol/DOPE-protamine, as well as
recombinant adeno-associated virus (AAV) vectors.
Introduction and background
In our recent era of molecular medicine, physicians are
compelled to think in terms of the genetic basis of disease,
the expectation being that pathology can be ultimately
explained as a collection of (genetically  influenced)
biochemical defects. CD, or N-acetyl aspartic acylase
deficiency, is a fatal childhood leukodystrophy that is
typified by lack of hydrolysis of N-acetyl asparate (NAA),
leading to a local build-up of NAA in the brain as well as a
NAA acidemia and aciduria. It was first presented in a case
report by Myrtelle Canavan in 1931 as a variant of Schilder's
'encephalitis periaxialis diffusa', a degeneration of the
medullary sheaths with sparing of the axons. As it turns out
the various cases described by Schilder were either multiple
sclerosis, adrenoleukodystrophy, or subacute sclerosing
panencephalitis [1], rather than CD and it was left to
subsequent investigators to elucidate the distinctive
morphological and biochemical  profile of CD. With a better
molecular understanding of disease processes and the
advent of more effective experimental therapies, the past
problems of identification and poor prognosis will greatly
improve.
The original Canavan patient presented with vomiting,
constipation, and lack of proper weight gain; the child failed
to meet developmental milestones such as grasping at
objects or holding up its head; the cranium grew
progressively and disproportionately large; vertical
nystagmus and a convergent strabismus were noted; the
initial hypotonia was later followed by symptoms of hyper-
reflexia. When the child died at age 16 months, an autopsy
demonstrated subcortical loss of myelin and diffuse and
marked edema of the white matter [2]. The distinctive
spongiform pathology of the brain in CD, said to resemble 'a
sponge soaked with water' [3], was later clarified in the
literature by Van Bogaert and Bertrand [4]. The biochemical
defect common to all CD patients, however, was not
discovered until 1988, when Matalon and coworkers
discovered the mutant aspartoacylase (ASPA) enzyme [5•].
Although the ASPA gene was cloned in 1993 and the most
common mutations have now been isolated [6], the cellular
pathology that results in CD has yet to be elucidated and the
contribution of the substrate molecule (NAA) is still unclear.
Symptoms and pathology
Many symptoms of CD are common to other organic acid
disorders and include megaloencephaly, ataxia,
myoclonus and extrapyramidal symptoms (hypotonia,
dystonia and dyskinesia) [7]. The typical progression of
extrapyramidal signs is hypotonia followed by a gradual
increase of tone, leading eventually to rigidity, spasticity
and choreoatheosis. In addition, there is usually
considerable psychomotor and mental retardation,
manifested by apathy and a failure to meet developmental
milestones. Partial or grand mal seizures are also
common, and in studies by Traeger and Rapin, 63% of CD
patients had some form of epilepsy [8]. Certain features of
CD such as macrocephaly, mental retardation, spasticity
and optic atrophy are found in other leukodystrophies,
such as Tay Sach's and Alexander disease.
Apart from the elevation of NAA, which is unique to CD,
the characteristic 'spongy' degeneration in CD is the most
unusual feature of the pathology. A similar morphological
change can occur after exposure to certain toxins (eg, triethyl
tin, cuprizone, iproniazid). The first ultrastructural study
was published by Adachi in 1966, and demonstrated large
spaces within the myelin sheaths, as well as swollen
astrocytic cells and processes [9]. Others have noted a loss of
demarcation of the cortical white and grey matter, with
multiple vacuoles (up to 200 µm in diameter) throughout the
deep cortex and subcortical white matter. The spongy
pathology is characterized by an accumulation of excessive
fluid mainly within the myelin lamellae and astrocytic
processes [10]. Elongated mitochondria are typically
observed in the astrocytes. The nuclei and cell bodies of
neurons are generally intact without evidence of
abnormality [9]. Vacuolated oligodendrocytes are seen
occasionally, but most oligodendroglia are normal even in
areas of expanded  extracellular space and disintegrating
myelin sheaths. In the cortex, the 'sponginess' was found in
one study to correspond to swollen astrocytes, whereas in
white matter the vacuoles were formed by the intramyelinic
and extracellular fluid (ECF) [11]. In general the entire
central nervous system (CNS) is affected, with vacuolization
of white matter most evident in the cerebellum and
brainstem [12].
The relationship of NAA and ASPA to the
disease pathology
It is interesting that NAA is strictly compartmentalized
within the brain. NAA is synthesized only in the CNS, and
more specifically only within the mitochondria of neurons
488 Current Opinion in Molecular Therapeutics 1999 Vol 1 No 4
[13•,14]. It is found in high concentrations within neurons (5
to 10 mM) and it has long been considered a neural-specific
marker. On the other hand, ASPA has a wide tissue
distribution and it has been isolated from human kidney,
adrenal glands, lung, liver and skin [15••]. Within the brain,
ASPA is predominantly localized to the white matter, where
it is found in highest concentration among the axons and
myelin [16]. It has been reported that ASPA in gray matter
and blood components is undetectable [17]. This fact is
significant, because bone marrow transplant (BMT) has been
suggested as a possible ameliorative measure to lower NAA
in CD, and a patient recently received a BMT in the hope of
lowering systemic NAA [Krivit W, personal
communication]. BMT has been used in a number of other
CNS leukodystrophies [18], but its relevance in CD is
unknown.
Interstitial levels of both NAA and NAAG (N-acetyl-
aspartyl-glutamate, a biosynthetic product of NAA) are
elevated in CD. Neurons have a several-fold increased level
of NAA over white matter and yet the gray matter is spared
significant pathological change in CD, which argues against
a directly toxic role of NAA in the pathogenesis. However,
one hypothesis has been that high levels of NAA may be
toxic when applied to glial cells, yet neuronal cells are
spared. Studies on NAA and NAAG, demonstrate limited
binding at NMDA receptors and suggest the possibility of
toxic effects on neurons in vitro [19]; relatively low levels
(approximately 1 mM) of either NAA or NAAG are not
neurotoxic when applied to neuronally-enriched cell culture
[20], but higher levels of NAA (approximately 3 to 10 mM)
can elevate intracellular calcium up to 3-fold [21]. Some glial
cells are known to be susceptible to glutamate excitotoxicity,
but the fact that ultrastructural studies have shown limited
oligodendrocyte cell body involvement in CD argues against
a simple cytotoxic hypothesis of NAA or NAAG for those
cells.
The normal function of NAA has been debated for some time.
It has been suggested that a main role is as an acetyl donor in
lipogenesis. The acetyl group of NAA is incorporated into a
variety of lipids in brain and liver; it is converted to acetate and
acetyl-CoA in both tissues [22]. Therefore one hypothesis is
that NAA functions as a storage form of acetate and for acetyl-
CoA production. The implication for CD is that a decrease in
available acetyl-CoA (through a failure of ASPA to cleave
NAA) would lead to a failure of acetyl-CoA requiring
reactions. This would explain the apparent demyelination of
CD [14]; however, it does not specifically account for the
spongiform changes.
Another hypothesis of normal NAA function is that it
functions as part of an osmotic (water) pump. Through
comparative anatomical studies of fish, amphibians, and
mammals, Baslow concluded that unhydrolyzed NAA in
the ECF functions as an 'osmolar diuretic' to draw out
water, which can congest the axons and disrupt the
myelin sheaths without destroying the axons [13•].
Although the mechanism was unclear at the time, the idea
of water imbalance causing demyelination was proposed
back in the 1960s. Van Bogaert and Bertrand advanced this
hypothesis, in which they noted that "retention of  water
in the nervous tissue breaks up the normal myelin and
edema in areas of intact myelin may destroy the latter…
the edematous swelling can precede the de-myelination:
one imagines in fact that the myelin destruction may
result from the spongy swelling" [3]. More recently, in vivo
microdialysis experiments have been performed in rats
that support an osmoregulatory role for NAA, in which
step exposure to hyposmotic media increases dialysate
levels of NAA [29•].
Baslow has suggested that NAA, NAAG, carnosine and
homocarnosine "probably have a common function as
regulators of cellular water efflux" [16]. When this water
efflux is accentuated through a failure of NAA degradation
in the extracellular space, intramyelinic swelling typical of
CD may result. Baslow has additionally proposed a
transcellular flow, driven by NAA efflux and breakdown,
with the maintenance of a high tissue-to-ECF gradient of
NAA and a continuous NAA efflux into the ECF. This
model predicts a mild aspartate deficit in CD caused by a
failure to degrade NAA. Baslow has described a 'near-field'
and a 'far-field' cycle for NAA. The purpose of the far-field
cycle would be to transport aspartate from the periphery,
perhaps using erythrocytes (which concentrate aspartate) as
a vehicle. The lack of CD pathology in utero is attributed to
the protective effect of the maternal circulation, which
supplies aspartate to the fetus. If hypo-aspartia indeed
constitutes an  important aspect of the pathology, this model
predicts that infusion of aspartate into ASPA-deficient
animals or humans might be beneficial if higher, but non-
toxic levels within the CNS are maintained [13•]. It has been
suggested by a number of investigators that a state of hypo-
aspartia induced by failure of the normal NAA cycle might
lead to a decreased generation of oxaloacetate (the rate-
limiting substrate for the tricarboxylic acid cycle) through a
decrease in transamination reactions, which could in turn
disrupt cellular metabolism; research groups are currently
collaborating with Keith Hyland to quantify (using HPLC
techniques) cerebroventricular metabolites that may support
or disprove this hypothesis.
The idea of osmolar disequilibrium as an underlying cause
of edema in CD is not new. Some researchers have looked
specifically at Na+/K+ transporters, given a similar
spongiform pathology that occurs as a result of treatment in
experimental animals with oubain, which blocks the Na+/K+
transporter and causes pathological swelling of astrocytes
and presynaptic axon terminals [9]. Yet there appears to be
no pathology specific to these transporters. In spongy
degeneration the synapses display a normal ATPase  activity
and the axon terminals are unchanged; however, the
mitochondrial ATPase activity is somewhat decreased,
perhaps a marker of overstrained mitochondria and a
possible cause of the typical astrocytic swelling [9]. The
abnormal mitochondrial ultrastructure in CD tends to
suggest a role for metabolic or energetic causes in the
pathogenesis of CD, and it is possible that water imbalance
acts to exacerbate co-existing metabolic or energetic
problems.
In summary, there are several possible theories of the
normal role of NAA (lipid biosynthesis precursor, TCA
intermediate and osmolyte) and its role in the pathology of
CD when ASPA is deficient (cytotoxic, metabolic and
osmotic). The relative importance of each of these factors,
and how they may work together, has yet to be determined.
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Prenatal diagnosis
CD is associated with a marked increase in NAA levels in
cerebral spinal fluid (CSF), plasma and urine. This biological
marker became the primary method of diagnosis following
identification of ASPA deficiency in the late 1980s [5•]. Prior
to that time, surgical brain biopsy in conjunction with
computed tomography (CT) was the best method for
diagnosis. Prenatal genetic counseling and testing is now
available for CD, and is recommended for Ashkenazi Jewish
descendents (who have a carrier frequency of approximately
1 in 40) and all other patients in a high-risk group.
Polymerase chain reaction (PCR)-based genetic testing is
available for well-characterized mutations.
Canavan disease and symptomatic therapies
The severity of CD symptoms varies significantly on a case by
case basis. The clinical course of the disease is relentlessly
progressive, although the rate of deterioration is variable. At
present there is no treatment of proven efficacy, although gene
therapy seems to be the most promising approach, particularly
as vector design and delivery improves (Figure 1). Current
management is based on a combination of physiotherapy
procedures and supportive strategies such as dietary
modifications (eg, ketogenic diet), nutritional supplements (eg,
carnitine, calcium acetate) and palliative drug regimens such
as anti-epileptics, anxiolytics and diuretics.
Calcium acetate (15 to 30 mg/kg per day) and acetazolamide
(5 to 7 mg/kg per day) administration may be indicated in
CD. Controlled studies have not yet been performed, but
there is anedoctal evidence suggesting that combination of
these two drugs is associated with improvements in
neurological function in children with CD  [Kolodny E,
personal communication]. The calcium acetate (PhosLo) was
originally given to CD patients to control
hyperphosphatemia, and was incidentally found to improve
mental function, possibly through increased lipid synthesis;
the diuretic is intended to decrease ECF in the brain.
Another possible therapeutic approach might include the
use of the recombinant ASPA enzyme delivered directly into
the brain of children with CD. This approach has not been
developed sufficiently to demonstrate all the risks (in
addition to surgery), but based on the outcome of an Israeli
trial on brain delivery of hexaminadase A to children with
Tay Sach's disease, such an approach is unlikely to afford
adequate or long-term benefits [23].
Canavan disease and gene therapy
Considered together, the leukodystrophies are attractive
candidates for replacement gene therapy, considering the
catastrophic effects of the diseases, the absence of other
effective treatments and the fact that a single gene
etiology has been identified for a number of these
disorders. CD as a target is particularly attractive because
the pathology is restricted to the brain rather than being
multisystemic, and the effect of gene transfer (ASPA
delivery) can be followed non-invasively using 1H-NMR
of brain NAA levels.
There are a number of obstacles to effective AAV-mediated
ASPA gene therapy, among them the problem of targeting
all the affected cells and achieving sufficiently long-term
levels of gene expression. On the bright side, it is possible
that only a small fraction of transduced cells might correct
the abnormal ASPA function in CD patients. Studies of
heterozygote carriers of ASPA mutation alleles
demonstrated that ASPA activity in fibroblasts might be
only 40% that of non-carriers, yet heterozygotes have no
phenotype [24]. Therefore even modest gains in enzyme
activity may be sufficient to lower NAA and to have an
effect on the disease course. In addition, there is a late-onset
variant of CD (onset of severe symptoms after the age of 5
years) with less elevation of NAA in the brain, which is
hypothesized to have a milder ASPA defect than the early-
onset CD patients. In two children with this juvenile form of
the disease, urine NAA levels were elevated, but CNS levels
of NAA were initially normal as measured by1H-NMR [25].
Figure 1. The first four children with Canavan disease enrolled in the gene therapy phase I trial (post-gene delivery).
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Figure 2. Schematic representation of the gene therapy trial.
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In these two patients, activity of ASPA in skin fibroblasts
was only 4 to 5% of wild-type, yet the children had minimal
leukodystrophy at the ages of 2 and 4 years. It is possible
that this milder phenotype, in which brain NAA elevation is
less pronounced and symptoms are delayed, may be
reproduced by overexpressing ASPA in the brain.
Despite the hurdles that the brain poses for gene therapy,
significant advances have been made in two delivery
systems (liposomal and viral) for gene transfer to the CNS.
The first is a second generation, liposome-based delivery
system based on the DC-Chol/DOPE together with
protamine as a DNA-condensing agent. The most recent is
recombinant AAV vector: a defective, human non-
pathogenic parvovirus. It has been shown that AAV can
safely and effectively transduce mammalian neurons and
glia, and in a rodent model of Parkinson's disease, long-term
phenotypic correction has been shown [24]. Furthemore, as
AAV is extremely small (only 20 nm), using strategies to
modify the blood-brain barrier it may more readily cross
into and through the brain parenchyma.
Over the past 5 years, investigators have generated sufficient
safety data in rats and primates to achieve approval for two
clinical phase I studies (University of Auckland, New
Zealand 1996, Yale University/Thomas Jefferson
University/Advanced Therapies Inc, US 1998) for ASPA
gene therapy in children affected by CD (Figure 2); the
development of a homologous knockout mouse model of
CD is still in progress, and therefore no efficacy data could
be generated at the time that the clinical studies were first
approved. An ASPA-expressing plasmid with the
transcription unit flanked by AAV-inverted terminal repeats
(ITRs) was constructed and tested in vitro for ASPA
expression, and high levels of enzyme activity were
obtained; this plasmid was then used in a non-viral vector
complex for animal expression and  toxicity studies. ASPA
transgene expression was observed at the level of mRNA
using reverse transcriprase (RT)-PCR with primers specific
to the vector-encoded ASPA. There is still no monoclonal
antibody to ASPA, and therefore detection at the protein
level was not possible, except for fusion gene constructs.
As a delivery method, a novel liposome-encapsulated,
condensed plasmid DNA (LPD) was chosen [26]; the
expression plasmid consisted of the early cytomegalovirus
(CMV) promoter, the human aspartoacylase (ASPA) full-
length cDNA and a SV40 polyA flanked by AAV 145 base
pair ITRs. The LPD complex was designed to be delivered
into the cerebral ventricles, the rationale being that a large
surface area of brain tissue could be transduced if the vector
penetrated the ependymal cells. Results in animals showed
expression in ependyma (periventricular cells) with some
limited expression extending into parenchyma. The
liposome used in the gene therapy trials was originally
synthesized in January 1992 at the University of Pittsburgh
and was the same batch used for other gene therapy phase I
trials [27,28]. Poly-L-lysine was used as a cationic polymer
during the first gene therapy trial in New Zealand in two
children, and protamine in 14 children during the phase I
trial in the USA.
This intervention represented the first human gene therapy
trial for a neurodegenerative disease, and an important
'proof-of-principle' study of an otherwise fatal disease.
Initial results appear promising, bearing in mind that the
endpoints of phase I studies are those of safety and
tolerability. Following the demonstration of safety, efforts
are being directed towards further defining the efficacy of
this treatment, using a number of clinical outcome measures:
CSF analysis, MRI (myelin quantification), 1H-NMR
spectroscopy (NAA quantification), evoked potentials
(auditory, visual, somatosensory and brainstem),
neurological evaluation, and parental reports with
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videotapes. Preliminary (unpublished) data using AAV-ITR-
based condensed plasmid vectors suggest that non-viral, in
vivo gene therapy of CD is safe and may be associated with
some biochemical, radiological and clinical benefit.
Currently our efforts are focused on the improvement and
testing of high-titer, ultrapure ASPA-AAV viral vectors for
use in future clinical trials. The original phase I safety trial is
ongoing in terms of data collection, but has paused in terms
of vector administration, in order to accommodate vector
improvements and testing; it is hoped that new AAV
vectors, driven by a variety of brain-specific promoters, will
afford greater long-term expression of the deficient enzyme.
Conclusion
CD is a noteworthy and tragic disease, yet the importance of
this study extends well beyond CD. Progress toward safe
and effective gene therapy will help in the development of
better treatments for a host of other neurological disorders,
whether lysosomal, peroxisomal, metabolic or multifactorial.
This century has seen ground-breaking medical discoveries,
which have uncovered the biochemical pathways as well as
the genetic identity underlying many diseases; the crucial
steps involved in designing an effective gene-based therapy
include determining the function of the key gene products
associated with a given disease, identifying and
characterizing the relevant genes, and finally manipulating
them at will with the aid of new generation delivery vectors.
This is the ultimate goal and challenge of gene therapy: to
make biochemistry the servant of our genetic interventions.
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